Activation of WNT/b-catenin signaling results in resistance to PI3K/mTOR dual inhibitor in co-existing KRAS and PIK3CA mutant colorectal cancer cells

被引：0
|
作者：
Park, Ye-Lim
Kim, Hwang-Phill
Cheon, Seul-Ki
Kang, Jun-Kyu
Lim, Yoojoo
Song, Sang-Hyun
Han, Sae-Won
Kim, Tae-you
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5214
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5214
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
    Park, Ye-Lim
    Kim, Hwang-Phill
    Cho, Young-Won
    Min, Dong-Wook
    Cheon, Seul-Ki
    Lim, Yoo Joo
    Song, Sang-Hyun
    Kim, Sung Jin
    Han, Sae-Won
    Park, Kyu Joo
    Kim, Tae-You
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) : 389 - 401
  • [2] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
    Kim, Areumnuri
    Lee, Jung-Eun
    Lee, Seung-Sook
    Kim, Cherin
    Lee, Sun-Joo
    Jang, Won-Suk
    Park, Sunhoo
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (04) : 984 - 996
  • [4] Dual PI3K/mTOR inhibition as a treatment strategy for PIK3CA and APC mutant colorectal cancers
    Payne, Susan
    Foley, Tyler
    Pasch, Cheri
    Yueh, Alexander
    Korkos, Demetra
    Van De Hey, Dana
    Clipson, Linda
    Deming, Dustin
    CANCER RESEARCH, 2016, 76
  • [5] Treatment of PIK3CA and APC mutant colorectal cancers with dual PI3K/mTOR inhibition.
    Tyler, Foley
    Payne, Susan
    Yeuh, Alexander
    Van DeHey, Dana
    Pasch, Cheri
    Clipson, Linda
    Matkowskyj, Kristina
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Differential response to a dual PI3K/mTOR inhibitor in PIK3CA mutant urothelial cancer patient derived xenografts
    Elbanna, May F.
    Ciamporcero, Eric
    Adelaiye, Remi
    Orillion, Ashley
    Chintala, Sreenivasulu
    Pili, Roberto
    CANCER RESEARCH, 2016, 76
  • [7] Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
    Foley, Tyler M.
    Payne, Susan N.
    Pasch, Cheri A.
    Yueh, Alex E.
    Van De Hey, Dana R.
    Korkos, Demetra P.
    Clipson, Linda
    Maher, Molly E.
    Matkowskyj, Kristina A.
    Newton, Michael A.
    Deming, Dustin A.
    MOLECULAR CANCER RESEARCH, 2017, 15 (03) : 317 - 327
  • [8] Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
    Chen, Zhihang
    Wang, Chun
    Dong, Hao
    Wang, Xing
    Gao, Feng
    Zhang, Sen
    Zhang, Xiaolong
    MOLECULAR MEDICINE, 2020, 26 (01)
  • [9] Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by PI3K/Akt/Raptor pathway
    Zhihang Chen
    Chun Wang
    Hao Dong
    Xing Wang
    Feng Gao
    Sen Zhang
    Xiaolong Zhang
    Molecular Medicine, 2020, 26
  • [10] Activation of the MACC1/PIM/cMyc axis confers resistance to PI3K/mTOR inhibition in PIK3CA mutant NSCLC
    Moore, Gillian
    Elbai, Samira
    Heavey, Susan
    Finn, Stephen
    O'Neill, Michael
    Gately, Kathy
    MOLECULAR CANCER RESEARCH, 2020, 18 (10) : 48 - 48
12345